All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
The efficacy of allogeneic cell therapeutics for regenerative or oncology indications can be compromised by the emergence of antibodies against those cells, as observed in clinical trials. To overcome this limitation, scientists from the University of California and collaborators have developed a gene engineering approach providing antibody protection for cell therapeutics. The new approach to protecting cells from antibody-mediated cellular cytotoxicity (ADCC) relies on the overexpression of the IgG receptor CD64.